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Abstract
Objectives: To develop a sleep hypoxia (SH) in emphysema (SHE) rat model and to explore whether SHE results in more
severe hepatic inflammation than emphysema alone and whether the inflammation changes levels of coagulant/
anticoagulant factors synthesized in the liver.
Methods: Seventy-five rats were put into 5 groups: SH control (SHCtrl), treated with sham smoke exposure (16 weeks) and
SH exposure (12.5% O2, 3 h/d, latter 8 weeks); emphysema control (ECtrl), smoke exposure and sham SH exposure (21% O2);
short SHE (SHEShort), smoke exposure and short SH exposure (1.5 h/d); mild SHE (SHEMild), smoke exposure and mild SH
exposure (15% O2); standard SHE (SHEStand), smoke exposure and SH exposure. Therefore, ECtrl, SHEShort, SHEMild and
SHEStand group were among emphysematous groups. Arterial blood gas (ABG) data was obtained during preliminary tests.
After exposure, hepatic inflammation (interleukin -6 [IL-6] mRNA and protein, tumor necrosis factor a [TNFa] mRNA and
protein) and liver coagulant/anticoagulant factors (antithrombin [AT], fibrinogen [FIB] and Factor VIII [F VIII]) were evaluated.
SPSS 11.5 software was used for statistical analysis.
Results: Characteristics of emphysema were obvious in emphysematous groups and ABGs reached SH criteria on hypoxia
exposure. Hepatic inflammation parameters and coagulant factors are the lowest in SHCtrl and the highest in SHEStand
while AT is the highest in SHCtrl and the lowest in SHEStand. Inflammatory cytokines of liver correlate well with coagulant
factors positively and with AT negatively.
Conclusions: When SH is combined with emphysema, hepatic inflammation and coagulability enhance each other
synergistically and produce a more significant liver-derivative inflammatory and prothrombotic status.
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Introduction
Chronic obstructive pulmonary disease (COPD), in which
chronic systemic inflammation is a central component, is a
growing global epidemic that is particularly important in
developing countries [1]. It is expected that in 2020 COPD will
become the third leading cause of death worldwide [2]. In
humans, COPD includes two major subtypes, chronic bronchitis
and emphysema. The emphysema subtype seems to present more
obvious systemic inflammation, suggesting that it may be more
prone to systemic consequences of COPD compared to subtype
without emphysema [3]. Sleep hypoxemia (SH) in The Interna-
tional Classification of Sleep Disorders: Diagnostic and Coding
Manual 2 (ICSD-2) is defined as ‘‘an SpO2 (oxyhemoglobin
saturation) during sleep of .30% of total sleep time with an SpO2
of ,90% in subject with a baseline awake SpO2 of $90% ’’[4,5].
The phenomenon of SH complicating emphysema has been
recognized for at least 50 years [6] and has been noted in
polysomnography (PSG) studies of emphysematous patients
recently [7]. Because of a number of factors, mainly including:
alveolar hypoventilation, airway obstruction, hyperinflation,
respiratory muscle dysfunction, blunted ventilatory responses to
hypoxia and ventilation-perfusion mismatch, emphysematous
patients run a high risk of developing SH [8–10]. Compared to
their non-SH brethren, emphysematous patients with SH have
greater degrees of pulmonary hypertension and cor pulmonale
[11], require more frequent hospitalizations, sustain higher
mortality rates [12–15] and demonstrate systemic evidence of
pronounced inflammatory activation [16] which may cause
inflammatory damages to the liver as well.
Increased risk of thrombotic events occurs in COPD [17].
Venous thromboembolism (VTE) occurs with increased frequency
in patients with COPD which may be due to hypercoagulability as
a result of hypoxia [18]. Most of the coagulant factors and
anticoagulant factors are synthesized in liver and among them,
antithrombin (AT), fibrinogen (FIB) and Factor VIII (F VIII) play
very important roles in coagulation cascade. AT, as a central
anticoagulant in mammalian circulation system, binds and
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thrombin) directly [19]; FIB, a soluble glycoprotein, is converted
by thrombin into fibrin during blood coagulation and is then cross
linked by factor XIII to form blood clot [20]; F VIII, an essential
blood clotting factor also known as anti-hemophilic factor, is
bound to von Willebrand factor (vWF) to form a stable complex in
circulating blood and once activated by thrombin it dissociates
from the complex to interact with Factor IXa and participates in
the coagulation cascade for crosslinking into a blood clot. Without
the protection of vWF, activated F VIII is proteolytically
inactivated and cleared from the blood stream quickly [21].
Hypoxia induces systemic inflammation and acts as an
aggravating factor of liver inflammation [22–24]. Compared with
isolated emphysema, it has not yet been clearly elucidated whether
SH in emphysema can cause more obvious inflammation in liver
and whether the inflammation changes levels of coagulant/
anticoagulant factors synthesized in the liver. To examine this, we
exposed emphysematous rats (the pre-existing emphysema was
formed through smoke exposure for 16 weeks) to hypoxia during
sleep in a custom-made chamber therefore developing a novo rat
model of SH in emphysema (SHE); with this model the
inflammatory cytokines of the liver was studied and the four
important coagulant/anticoagulant factors just mentioned above
were measured. The inflammatory cytokines we measured in this
study included interleukin -6 (IL-6, a classic pro-inflammatory
cytokine) mRNA and protein levels, tumor necrosis factor a
(TNFa, a classic pro-inflammatory cytokine) mRNA and protein
levels.
Methods
The overall experimental protocol is hypoxia exposure during
sleep on the base of pre-existing emphysema which is caused by 16
weeks of smoke exposure followed by exploring inflammatory and
coagulant/anticoagulant factors of the liver. Institutional Review
Board of Tianjin Medical University General Hospital approved
the ethical and methodological aspects of the investigation (TMU
IRB Approving Number: EA-20080002.).
Animal cigarette smoke exposure
Seventy-five male Wistar rats weighing 150,180 g at age of 7
weeks (provided by Model Animal Center of Radiological
Medicine Research Institute, Chinese Academy of Medical
Science, license No.: SCXK Tianjin 2005-0001) were divided
into 5 groups of 15 according to exposure conditions. Animals
were housed in standard laboratory cages (5 per cage) and allowed
food and water ad libitum. Rats were passively exposed to the
smoke of 15 commercial unfiltered cigarettes (Daqianmen
TM,
Yunnan, China) for 30 minutes twice daily, in the morning (before
9 am) and in the evening (after 5 pm), for 16 weeks (W 1 to the end
of W 16) continuously in a custom-made plexiglas chamber
(0.6 m
3 with 5 poles in side wall for ventilation, 15 rats per batch).
Content of tar was 18 mg for every cigarette and concentration of
smog was about 15% (V/V) within the housing chamber through
burning of 5 cigarettes concurrently. Control rats were exposed to
a sham environment otherwise the same condition except of
cigarette burning [25].
Animal electroencephalogram monitoring and SH
exposure
A week prior to the experimental exposure, two stainless steel
screws attached to insulated wires were implanted in the skull
(from bregma: anteroposterior, +2 mm, mediolateral, 22 mm;
and anteroposterior, 23 mm, mediolateral, +2 mm) of all
recruited rats to record electroencephalogram (EEG) [26]. For
electrophysiological recording, a lightweight shielded cable was
connected to the plug on the rats’ heads which permitted free
movement of the rats within the cage. The signals were routed to
an electroencephalograph (Nicolet Bravo, USA) so that sleep
stages could be monitored conveniently and continuously. We
designed a hypoxia pattern definitely different from intermittent
hypoxia seen in previous literatures [27,28] used in study on
obstructive sleep apnea (OSA) and our focused hypoxia pattern
was an ‘‘intermittent continuous hypoxia’’ often seen in SH of
emphysematous patients [4,5]. Briefly, a gas control delivery
system [29] was designed to regulate the flow (2.5 L/min) of
premixed gas (21% O2, 15% O2 or 12.5% O2) or clean air
continuously into a customized SH housing chamber (volume
about 10 L) to maintain a designated continuous hypoxia or
normoxia environment. A series of programmable solenoids and
flow regulators altered the fractional concentration of inspired
oxygen through software edited with Visual C
++ computer
language that controlled the durations of hypoxia/normoxia
cycles, which could divide total hypoxia time (1.5 h or 3 h) into 4
periods evenly (22.5 min or 45 min each) and distribute these
hypoxia periods into physiological sleep time of Wistar rats
identified by EEG (9 AM to 5 PM as estimated). The chamber was
equipped with a humidifier, thermostat, and molecular sieve to
maintain an inner temperature of 22 uC, humidity of ,45% and a
germfree circumstance. O2 and CO2 concentration monitors
(Hamilton, Switzerland) were used to determine the environmen-
tal situation in the housing chamber for rats.
Exposure protocol
Seventy-five male Wistar rats were seperated into 5 groups of 15
as follows: A. SH control group (SHCtrl), sham smoke exposure
(W 1 to W 16) and true SH exposure (12.5% O2, 3 h, W 9 to W
16); B. Emphysema control group (ECtrl), true smoke exposure
(W 1 to W 16) and sham SH exposure (21% O2, 3 h, W 9 to W
16); C. Short SHE group (SHEShort), smoke exposure (W 1 to W
16) and short SH exposure (12.5% O2, 1.5 h, W 9 to W 16); D.
Mild SHE group (SHEMild), smoke exposure (W 1 to W 16) and
mild SH exposure (15% O2, 3 h, W 9 to W 16); E. Standard SHE
group (SHEStand), smoke exposure (W 1 to W 16) and SH
exposure (12.5% O2, 3 h, W 9 to W 16). Therefore, the ECtrl,
SHEShort, SHEMild and SHEStand group were expected
emphysematous groups according to experimental design.
Preliminary experiment to get the arterial blood gas
(ABG)
Two days before the end of exposure period (end of W 16 – 2 d),
5 rats were selected randomly from each group to obtain ABG
data. After anesthetization (10% chloral hydrate, 0.3 mL/100 g
body weight intraperitoneally), the right femoral artery of selected
rats was cannulated to obtain blood samples for monitoring ABG
at anytime as necessary. At the end of treatment (end of W 16),
arterial blood samples (0.7 mL each) were drawn under the
following conditions:
Point 1: Wakefulness in SHCtrl group with clean air exposure
(without emphysema, awake, 21% O2).
Point 2: Slow wave sleep period in SHCtrl group with clean air
exposure (without emphysema, sleep, 21% O2).
Point 3: Slow wave sleep period in SHCtrl group with SH
exposure (without emphysema, sleep, 12.5% O2).
Point 4: Wakefulness in ECtrl group with clean air exposure
(emphysema, awake, 21% O2).
Point 5: Slow wave sleep period in ECtrl group with clean air
exposure (emphysema, sleep, 21% O2).
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exposure (emphysema, sleep, 15% O2).
Point 7: Slow wave sleep period in SHEStand group with SH
exposure (emphysema, sleep, 12.5% O2).
For each blood sample collected, ABG analysis included measure-
ments of partial oxygen pressure (PaO2), partial carbon dioxide
pressure (PaCO2), arterial oxygen saturation (O2Sat) and pH value.
Measurements for AT, FIB, F VIII and vWF
The remaining 10 rats from each group were used for following
experiments at the end of exposure. Blood samples were obtained
from tail veins using sodium citrate in order to perform AT, FIB, F
VIII and vWF tests through an ACL 9000 automated coagulation
analyzer (Beckman Coulter, CA) with proper reagent kits (Dade
Behring, IL) in the core hospital laboratory. Activities of AT and F
VIII were measured in percent to standard plasma activity and
concentration; the concentration of FIB was expressed as mg/dL;
and the concentration of vWF Ag was reported as percentage in
relation to a photometric extinction of standard plasma.
Histologic identification of emphysema
After anesthetization and isolation of lungs, all lung samples
were inflated intrabronchially with 10% formalin at a constant
transpulmonary pressure of 25 cm of formalin for at least 18 hours
with samples impregnated wholly in formalin at the same time.
Then lung blocks were fixed, embedded, cut and stained. Images
were captured at 40 X and were saved as JPEG files [30]. Pictures
were then given to pathologists with expertise in the pathology of
emphysema for assessment.
Measurements for IL-6 mRNA and protein levels, TNFa
mRNA and protein levels
For liver tissue preparation, blocks from each rat were frozen in
liquid nitrogen and stored at 280uC in order to analyze IL-6 and
TNFa. The levels of IL-6 and TNFa gene expression were
quantified using real time RT-PCR analysis. Total RNA was
isolated from rat liver samples using Trizol reagent, followed by
purification with RNeasy Mini Kit (Qiagen, MD). Total RNA
(1 mg) was reverse transcribed with murine leukemia virus reverse
transcriptase and random hexamer primers. Primers for IL-6 and
TNFa were designed using Primer Express software (version 2.0,
Applied Biosystems, CA). The primer sequences used in this study
were as follows: IL-6, 59-CTG ATT GTA TGA ACA GCG ATG-
39 (forward) and 59-GAA CTC CAG AAG ACC AGA GC-39
(reverse); TNFa, 59-GAC CCT CAC ACT CAG ATC ATC TTC
T-39 (forward) and 59-CCT CCA CTT GGT GGT TTG CT-39
(reverse); GAPDH, 59-CCT GGA GAA ACC TGC CAA GTA T-
39 (forward) and 59-AGC CCA GGA TGC CCT TTA GT-39
(reverse). The SYBR green DNA PCR kit (Applied Biosystems,
CA) was used for real time PCR analysis. Gene expression data
was expressed using cycle time values normalized with internal
GAPDH, and relative differences between control and treatment
groups were calculated and expressed as relative increases setting
control as 100%. The frozen liver blocks were also homogenized
in 100 mg tissue/ml cold lysis buffer (20 mM Tris, 0.25 M
sucrose, 2 mM EDTA, 10 mM EGTA, 1% Triton X-100 and 1
tablet of Complete Mini protease inhibitor cocktail/10 ml, Roche
Diagnostics, IN). Homogenates were centrifuged at 100,0006 g
for 30 min, supernatant was collected, and total protein levels
were determined using BCA protein assay reagent kit (PIERCE,
WI). The protein levels of liver IL-6 and TNFa were measured
with IL-6 and TNFa commercial enzyme-linked immunosorbent
assay (ELISA) kits (R&D Systems, MN).
Statistical Analysis
SPSS 11.5 (SPSS Inc., Chicago, IL) software package was used
for statistical analysis and illustration. Preliminary ABG data was
obtained and is displayed as a descriptive analysis. One way
analysis of variance (ANOVA) was performed for whole difference
and Bonferroni post hoc multiple comparisons were used to evaluate
differences between internal groups. Linear correlation analysis
and linear fitting were performed for influential power estimating
to see whether significant correlations exist between relevant
parameters. Unless otherwise stated, values were reported as mean
6 standard deviation (SD), and P,0.05 is considered statistically
significant.
Results
Figure 1 shows the pathologic pictures selected randomly from
emphysematous rats. Pathologic characteristics of emphysema,
though may be in different severities among groups, were obvious
in the emphysematous rats, including inflammatory cell infiltra-
tion, increasing of mean linear intercept and decreasing of mean
alveolar number per microscope field. (detail not provided in this
article) [31–33].
Table 1 summarizes the ABG results obtained from preliminary
experiments two days before the end of exposure period.The values
in this table are descriptive, not for comparing between groups.
PaO2 value of SHCtrl in SH(12.5%) is 55.08360.3971 mmHg and
PaO2 values of ECtrl in wakefulness, sleep, SH(15%) and
SH(12.5%) are 84.46763.6092, 73.40062.1615, 54.61762.0371
and 46.56762.2844 mmHg, respectively.
Table 2 demonstrates that all measured inflammatory param-
eters and coagulant factors are the lowest and AT (an
anticoagulant factor) the highest in SHCtrl. Inflammatory
cytokines and coagulant factors in SHEStand are the highest
except for AT and vWF. AT in SHEStand has a tendency to be
the lowest though does not attain statistical significance. For AT:
SHCtrl is the highest; ECtrl is lower than SHCtrl, higher than
SHEStand and not different with others; SHEStand is lower than
SHCtrl and Ectrl but not different with SHEShort and SHEMild.
For vWF: SHCtrl is the lowest; ECtrl is higher than SHCtrl, not
different with SHEMild and lower than others; SHEStand is not
different with SHEShort and higher than others. For FIB, F VIII,
IL-6 mRNA, IL-6 protein, TNFa mRNA and TNFa protein:
SHCtrl is the lowest; ECtrl is higher than SHCtrl and lower than
SHEStand; SHEStand is the highest. More detail comparing
results are shown in Table 2.
For demonstrating clearly, Figure 2 plots this data showing that
inflammatory cytokines of liver (represented with TNFa) and
coagulant factors (represented with FIB) increase obviously from
left to right (from SHCtrl to SHEStand, through other
emphysematous groups) whereas anticoagulant factor, AT, shows
the obverse tendency.
From the relatively high correlation coefficients seen in Table 3,
inflammatory cytokines of liver correlate very well with coagulant
factors positively and with AT negatively. Figure 3 illustrates these
correlations clearly. With the increasing of TNFa protein, FIB and
F VIII increase gradually and AT decrease obviously. Correlation
coefficients for TNFa protein with FIB, F VIII and AT are 0.853,
0.837 and 20.684, respectively, all P values ,0.01.
Discussion
Our model of emphysema, caused by smoke exposure and
identified with pathologic criteria, reflects partly the pathobiologic
features of emphysematous COPD which is induced commonly by
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chronic persistent inflammation in the lung [34]. This kind of
chronic inflammatory response of the lung in some COPD
patients may be associated with a significant systemic inflamma-
tory response with downstream adverse clinical health effects, such
as cardiovascular diseases, osteoporosis, diabetes, metabolic
syndrome [1] and increased risk of hospitalization and mortality
and is therefore a topic of increasing concern [35]. It has even
been suggested that COPD might be a part of a chronic systemic
inflammatory syndrome [36]. As the most important metabolic
organ, most inflammatory materials are synthesized in liver. In a
literature, it has been implicated that in COPD patients
inflammatory mediators generated in the lung may ‘‘spill over’’
into the circulation and then activate the liver to release
inflammatory proteins, which may be the real detrimental factors
to target organs and the resource of systemic inflammation. Liver
may play an important role in the COPD systemic inflammation
chain [37]. Not only a pro-inflammatory status, COPD may also
be in a pro-thrombotic status. There is an increased risk of
thrombotic events occurs in those with COPD and our concerned
coagulant factors, AT, FIB and F VIII, have all been influenced by
COPD [38,39]. In a cohort study of over 23,000 patients,
Curkendall [40] reported an increased risk of acute myocardial
infarction, stroke and pulmonary embolism in COPD. In a 5,451-
patient deep venous thrombosis (DVT) registry, 668 (12.3%) had
COPD as a comorbid condition [41]; and in 197 consecutive
COPD patients, prevalence of pulmonary embolism was about
25% [42]. Though thrombosis is a multifactorial state and involves
various processes such as platelet activation, endothelial cell injury,
and activation of coagulation-fibrinolysis system, a hypercoagula-
tive state may also be implicated with the increasing of these 3
hepatic factors we studied in the clotting system. Additionally,
although it normally presents a nonthrombogenic surface,
endothelium is capable of procoagulant activity and suppression
of native anticoagulant properties. Exposure to hypoxic environ-
ments typically shifts the endothelial phenotype toward that in
which anticoagulant characteristics are reduced and proinflam-
matory features dominate the endovascular milieu, therefore may
increase procoagulant activity [43,44] and inhibit fibrinolysis [45].
Inflammation that comes from hypoxia can promote the assembly
of the prothrombinase complex and subsequently generates
thrombin [46]. A study of healthy volunteers showed a transient
increase in markers of coagulation activation during exposure to
hypoxia [47]. Although these studies are done in vitro or in
healthy volunteers, which may be unethical in COPD patients,
further hypoxia, SH as an example, may worsen the preexisting
pro-coagulant state in COPD as well putatively.
According to ABG results obtained from preliminary experi-
ments and pathologic characteristics of smoke exposure rats, we
have made a rat model of SHE through simulating the status of
SH (with exposing rats to hypoxia during sleep period, as
diagnostic criteria from ICSD-2 [4–7]) in emphysematous rats
(caused by exposure to cigarette smoke for a long period of time
and identified with pathologic criteria [31–33]). Our SHE model,
in fact, is the ‘‘combination’’ of emphysema and SH, not a real
COPD sleep related hypoxia (SRH) which appears at the end
stage of COPD. In the real COPD SRH pattern, SRH is
secondary to COPD, not combined by an exogenous hypoxia
environment. As a rat model, for building a uniform hypoxia
severity and time period, our exposure pattern may be a
reasonable and feasible methodology and it does represent some
of the pathological characteristics of SRH.
Figure 1. Pathologic pictures were obtained from emphysematous rats, stained with hematoxylin/eosin (H/E), and captured with 40
X light microscopy. Scale at left lower represents the length of 1000 mm.
doi:10.1371/journal.pone.0013201.g001
Table 1. Descriptive ABG results from preliminary tests.
SHCtrl group ECtrl group
Wakefulness Sleep SH (12.5%) Wakefulness Sleep SH (15%) SH (12.5%)
PaO2 (mmHg) 110.60064.2000 94.28362.3353 55.08360.3971 84.46763.6092 73.40062.1615 54.61762.0371 46.56762.2844
PaCO2 (mmHg) 39.50062.5322 41.01762.9390 35.96760.2944 44.15062.1980 49.01762.6095 47.50062.0871 49.65060.9894
O2Sat (%) 99.08360.2483 97.00060.2000 85.05061.1362 94.78361.5484 91.91760.6524 85.85061.0173 83.45061.7593
pH 7.406836
0.015523
7.413336
0.017580
7.419836
0.001941
7.372006
0.019698
7.358176
0.005776
7.352836
0.007387
7.353836
0.004622
PaO2: arterial oxygen partial pressure, PaCO2: arterial carbon dioxide partial pressure, O2Sat: arterial oxyhemoglobin saturation.
doi:10.1371/journal.pone.0013201.t001
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F VIII) and inflammatory parameters we measured are higher in
emphysematous groups than those in SHCtrl when AT is higher in
SHCtrl, indicating that, at least compared with simple SH, the
emphysema (combined or not combined with SH) caused by
smoke exposure may lead to a more severe inflammation and
more obvious prothrombotic status. Among emphysematous
groups, shown in table 2 and more clearly in Figure 2,
inflammatory and prothrombotic tendency is significantly en-
hanced by SH, which is the evidence of synergism of emphysema
and SH in this pathologic pathway. Because SHEStand has more
severe inflammation and coagulabilty than SHEShort and
SHEMild, we may conclude a dose-dependent mechanism in this
synergism. In similar emphysema extent, the lower and longer
time period of SH exposure, the more significant this synergism is.
In our study, inflammatory parameters of the liver correlate well
with coagulant factors positively and with AT negatively. The
potential influence of inflammation on coagulation may contribute
further to thrombogenesis, while abnormal blood coagulation
contributes directly to the pathophysiology and mortality of
COPD, which means a more severe inflammatory state and a
vicious cycle may be created [29]. Figure 3 illustrates and
quantifies these correlations; it is clearly shown that with the
increasing inflammation there may be an increase in blood
coagulabilty.
As above mentioned, this SHE model represents some of the
characteristics of SRH. In SRH, alveolar hypoventilation appears
to play a major role, especially during rapid eye movement (REM)
sleep. This was demonstrated by Becker [48] in a study of nine
patients with underlying COPD. Compared with wakefulness,
Table 2. Coagulant/anticoagulant factors and hepatic inflammation status.
SHCtrl ECtrl SHEShort SHEMild SHEStand
Whole blood coagulation
AT: A (%) 116.262.53
* 107.3968.045
{ 103.7266.31
{ 101.864.278
1 99.0463.986
||
FIB (mg/dL) 151.5566.2789
* 177.4667.2485
/ 189.9865.2845
/ 182.762.7761
# 198.467.369
*
F VIII: C (%) 200.3664.8754
* 227.78610.3779
‘ 232.2664.1727
‘ 242.53614.5011
‘ 303.25632.9323
*
vWF: Ag (%) 56.0261.4650
* 64.4561.72
/ 70.268.6665
@ 66.2163.2102
# 71.9661.8506
x
Hepatic inflammtion cytokines
IL-6 mRNA (standardized) 99.99065.0538
* 142.14066.1437
* 226.03067.3423
* 244.87066.5323
* 288.26065.7514
*
IL-6 protein (ng/100 mg protein) 10.39061.1060
* 12.47061.2508
‘ 13.11061.5337
‘ 12.99061.2405
‘ 19.04061.6788
*
TNFa mRNA (standardized) 100.00066.1601
* 181.43064.4086
* 227.79068.7492
* 252.70069.8080
* 295.09068.5188
*
TNFa protein (ng/100 mg protein) 9.94060.5379
* 12.23060.4244
* 13.43060.5908
/ 14.01060.7125
x 16.86060.3373
*
Note:
Unless otherwise stated, there is significant difference in Bonferroni post hoc multiple comparisons compared with other groups.
*different with others;
{not different with SHEShort and SHEMild;
{not different with ECtrl, SHEMild and SHEStand;
1not different with ECtrl, SHEShort and SHEStand;
|| not different with SHEShort and SHEMild;
/ not different with SHEMild;
# not different with ECtrl and SHEShort;
‘ no difference among ECtrl, SHEShort and SHEMild;
@ not different with SHEMild and SHEStand;
x not different with SHEShort.
doi:10.1371/journal.pone.0013201.t002
Figure 2. TNFa protein and FIB increase from SHCtrl to SHEStand while AT shows the obverse tendency. Error bars: +/2 1 SD. P,0.05 is
considered statistically significant in Bonferroni post hoc multiple comparisons between internal groups. Unless otherwise stated, there is significant
difference compared with other groups. * different with others; /not different with SHEMild; x not different with SHEShort; { not different with
SHEShort and SHEMild; { not different with ECtrl, SHEMild and SHEStand; 1 not different with ECtrl, SHEShort and SHEStand; || not different with
SHEShort and SHEMild; # not different with ECtrl and SHEShort.
doi:10.1371/journal.pone.0013201.g002
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32% during REM sleep, predominantly because of a decrease in
tidal volume, measured with a pneumotachograph. Additionally,
arterial hypoxemia alone may be the product of worsening
ventilation-perfusion mismatch with a greater effective shunt [5].
Alveolar hypoventilation occurs predominantly during REM
sleep. Ventilation-perfusion mismatch can occur during non-
REM sleep episodes as well [8].
Fletcher [49] showed that 27% of 135 patients with COPD
with awake PaO2 exceeding 60 mm Hg had SRH. In another
study, up to 25% of patients with COPD exhibit SRH, despite
having a daytime PaO2 above 60 mm Hg [50]. Koo [51] found a
mean decrease in PaO2 of 13.5 mm Hg and a mean increase of
PaCO2 of 8.3 mm Hg during REM sleep in COPD subjects. In a
study of 16 COPD patients [7], the mean SaO2 was 9066% and
the lowest SaO2 during the night was 8368%. The percentage
total sleep time (TST) with a SaO2 less than 90% was 37645%.
Sergi [12] found that SRH in COPD patients may represent an
independent risk factor for the development of chronic respira-
tory failure in COPD patients with day-time PaO2 .60 mm Hg.
Fletcher [13] noted significantly decreased survival among
patients with SRH compared with those without. In a study
focused on the systemic effects of nocturnal hypoxemia in COPD
patients, the number of patients presenting C reactive protein
(CRP) levels above those considered normal was significantly
greater in the desaturation group which is the evidence of
pronounced inflammatory activation in COPD patients with
nocturnal hypoxemia. [16]
The necessity of treatment of isolated SRH in COPD has been
debated for many years [52]. American Thoracic Society
guidelines [53] for diagnosis and treatment of COPD recom-
mended increasing oxygen flow by 1 L/min during sleep in
patients undergoing long-term oxygen therapy (LTOT) to prevent
nocturnal oxygen desaturation. However, those recommendations
were not supported by some related studies. [9,54,55].
Through our study we can infer a potential pathologic pathway.
In our emphysematous rat model, inflammatory mediators in liver
increase and subsequently more coagulant factors are produced
and AT is suppressed. When SH is combined with emphysema,
synergistic effects appear, and the inflammation and coagulability
may enhance each other and produce a more significant
inflammatory and prothrombotic status which will lead to further
health problems, as its clinical implication. In conclusion, the
authors believe that along with optimal treatment for COPD,
therapy for increasing PaO2 to .60 mm Hg is also important for
the improvement of inflammation and coagulation, no matter
what method is used (LTOT, nocturnal non-invasive positive
pressure ventilation (NNIPPV), or medications).
Figure 3. AT correlates with TNFa protein negatively. FIB and F VIII correlate with TNFa protein positively.
doi:10.1371/journal.pone.0013201.g003
Table 3. Correlations between inflammatory parameters and coagulant factors/AT from liver.
AT FIB F VIII Score for liver
IL-6
mRNA
IL-6
protein
TNFa
mRNA
TNFa
protein
AT 20.713** 20.562** 20.742** 20.720** 20.534** 20.738** 20.684**
FIB 0.683** 0.921** 0.855** 0.689** 0.891** 0.853**
F VIII 0.709** 0.773** 0.866** 0.807** 0.837**
Score for liver 0.870** 0.695** 0.930** 0.867**
IL-6 mRNA 0.748** 0.968** 0.934**
IL-6 protein 0.768** 0.830**
TNFa mRNA 0.945**
TNFa protein
Linear correlation analysis coefficients are shown.
**P,0.01.
doi:10.1371/journal.pone.0013201.t003
Sleep Hypoxia on Emphysema
PLoS ONE | www.plosone.org 6 October 2010 | Volume 5 | Issue 10 | e13201Acknowledgments
We are grateful to the information and correction from Danielle Speer of
Division of Pulmonary and Critical Care Medicine in Duke University
Medical Center, Durham, North Carolina, USA.
Author Contributions
Conceived and designed the experiments: JF AC ByC. Performed the
experiments: JF QsW. Analyzed the data: JF QsW. Wrote the paper: JF.
References
1. Barnes PJ (2010) Chronic obstructive pulmonary disease: effects beyond the
lungs. PLoS Med 7: e1000220.
2. Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L (2001) Epidemiology
of chronic obstructive pulmonary disease (COPD). Respiration 68: 4–19.
3. Papaioannou AI, Mazioti A, Kiropoulos T, Tsilioni I, Koutsokera A, et al.
(2010) Systemic and airway inflammation and the presence of emphysema in
patients with COPD. Respir Med 104: 275–282.
4. American Academy of Sleep Medicine (2005) The international classification of
sleep disorders: diagnostic and coding manual; 2nd ed. WestchesterIL, pp
165–167.
5. Casey KR, Cantillo KO, Brown LK (2007) Sleep-related hypoventilation/
hypoxemic syndromes. Chest 131: 1936–1948.
6. Kardos P, Keenan J (2006) Tackling COPD: a multicomponent disease driven
by inflammation. MedGenMed 8: 54.
7. Krachman SL, Chatila W, Martin UJ, Nugent T, Crocetti J, et al. (2005) Effects
of lung volume reduction surgery on sleep quality and nocturnal gas exchange in
patients with severe emphysema. Chest 128: 3221–3228.
8. Brijker F, van den Elshout FJ, Heijdra YF, Folgering HT (2001) Underestima-
tion of nocturnal hypoxemia due to monitoring conditions in patients with
COPD. Chest 119: 1820–1826.
9. O’Donoghue FJ, Catcheside PG, Eckert DJ, McEvoy RD (2004) Changes in
respiration in NREM sleep in hypercapnic chronic obstructive pulmonary
disease. J Physiol 559: 663–673.
10. Orem JM, Lovering AT, Vidruk EH (2005) Excitation of medullary respiratory
neurons in REM sleep. Sleep 28: 801–807.
11. Chaouat A, Naeije R, Weitzenblum E (2008) Pulmonary hypertension in
COPD. Eur Respir J 32: 1371–1385.
12. Sergi M, Rizzi M, Andreoli A, Pecis M, Bruschi C, et al. (2002) Are COPD
patients with nocturnal REM sleep-related desaturations more prone to
developing chronic respiratory failure requiring long-term oxygen therapy?
Respiration 69: 117–122.
13. Fletcher EC, Donner CF, Midgren B, Zielinski J, Levi-Valensi P, et al. (1992)
Survival in COPD patients with a daytime PaO2 greater than 60 mm Hg with
and without nocturnal oxyhemoglobin desaturation. Chest 101: 649–655.
14. Nunes DM, Mota RM, de Pontes Neto OL, Pereira ED, de Bruin VM, et al.
(2009) Impaired sleep reduces quality of life in chronic obstructive pulmonary
disease. Lung 187: 159–163.
15. Lewis CA, Fergusson W, Eaton T, Zeng I, Kolbe J (2009) Isolated nocturnal
desaturation in COPD: prevalence and impact on quality of life and sleep.
Thorax 64: 133–138.
16. Mueller Pde T, Gomes MD, Viegas CA, Neder JA (2008) Systemic effects of
nocturnal hypoxemia in patients with chronic obstructive pulmonary disease
without obstructive sleep apnea syndrome. J Bras Pneumol 34: 567–574.
17. Undas A, Kaczmarek P, Sladek K, Stepien E, Skucha W, et al. (2009) Fibrin clot
properties are altered in patients with chronic obstructive pulmonary disease.
Beneficial effects of simvastatin treatment. Thromb Haemost 102: 1176–1182.
18. Sabit R, Thomas P, Shale DJ, Collins P, Linnane SJ (2010) The effects of
hypoxia on markers of coagulation and systemic inflammation in patients with
COPD. Chest 138: 47–51.
19. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL (1994) Antithrombin: the
principal inhibitor of thrombin. Semin Thromb Hemost 20: 353–372.
20. Doolittle RF (1984) Fibrinogen and fibrin. Annu Rev Biochem 53: 195–229.
21. Sadler JE (1998) Biochemistry and genetics of von Willebrand factor. Annu Rev
Biochem 67: 395–424.
22. Gonzalez NC, Wood JG (2010) Alveolar hypoxia-induced systemic inflamma-
tion: what low PO(2) does and does not do. Adv Exp Med Biol 662: 27–32.
23. Chao J, Wood JG, Gonzalez NC (2009) Alveolar hypoxia, alveolar macrophag-
es, and systemic inflammation. Respir Res 10: 54.
24. Fuhrmann V, Kneidinger N, Herkner H, Heinz G, Nikfardjam M (2009)
Hypoxic hepatitis: underlying conditions and risk factors for mortality in
critically ill patients. Intensive Care Med 35: 1397–1405.
25. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, et al. (2005) Simvastatin inhibits
cigarette smoking-induced emphysema and pulmonary hypertension in rat
lungs. Am J Respir Crit Care Med 172: 987–993.
26. Horner RL, Sanford LD, Annis D, Pack AI, Morrison AR (1997) Serotonin at
the laterodorsal tegmental nucleus suppresses rapid-eye-movement sleep in freely
behaving rats. J Neurosci 17: 7541–7552.
27. Feng J, Chen BY, Cui LY, Wang BL, Liu CX, et al. (2009) Inflammation status
of rabbit carotid artery model endothelium during intermittent hypoxia
exposure and its relationship with leptin. Sleep Breath 13: 277–283.
28. Feng J, Chen BY, Guo MN, Cao J, Zhao HY, et al. (2007) Changes of nuclear
factor-kappaB and intercellular adhesion molecule-1 in endothelial cells exposed
to various intermittent hypoxia. Zhonghua Jie He He Hu Xi Za Zhi 30:
202–206.
29. Feng J, Chen BY, Guo MN, Cao J, Zhao HY, et al. (2007) Interleukin-6 and
tumor necrosis factor-alpha levels of endothelial cells in different hypoxia modes:
in vitro experiment. Zhonghua Yi Xue Za Zhi 87: 774–777.
30. Wagner U, Staats P, Fehmann HC, Fischer A, Welte T, et al. (2006) Analysis of
airway secretions in a model of sulfur dioxide induced chronic obstructive
pulmonary disease (COPD). J Occup Med Toxicol 1: 12.
31. Thurlbeck WM (1967) Internal surface area and other measurements in
emphysema. Thorax 22: 483–496.
32. Cosio M, Ghezzo H, Hogg JC, Corbin R, Loveland M, et al. (1978) The
relations between structural changes in small airways and pulmonary-function
tests. N Engl J Med 298: 1277–1281.
33. Birrell MA, Wong S, Hele DJ, McCluskie K, Hardaker E, et al. (2005) Steroid-
resistant inflammation in a rat model of chronic obstructive pulmonary disease is
associated with a lack of nuclear factor-kappaB pathway activation. Am J Respir
Crit Care Med 172: 74–84.
34. Barnes PJ, Celli BR (2009) Systemic manifestations and comorbidities of COPD.
Eur Respir J 33: 1165–1185.
35. Mannino DM, Thorn D, Swensen A, Holguin F (2008) Prevalence and
outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur
Respir J 32: 962–969.
36. Fabbri LM, Rabe KF (2007) From COPD to chronic systemic inflammatory
syndrome? Lancet 370: 797–799.
37. van Eeden SF, Sin DD (2008) Chronic obstructive pulmonary disease: a chronic
systemic inflammatory disease. Respiration 75: 224–238.
38. Vaidyula VR, Criner GJ, Grabianowski C, Rao AK (2009) Circulating tissue
factor procoagulant activity is elevated in stable moderate to severe chronic
obstructive pulmonary disease. Thromb Res 124: 259–261.
39. Tapson VF (2005) The role of smoking in coagulation and thromboembolism in
chronic obstructive pulmonary disease. Proc Am Thorac Soc 2: 71–77.
40. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, et al. (2006)
Cardiovascular disease in patients with chronic obstructive pulmonary disease,
Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol
16: 63–70.
41. Goldhaber SZ, Tapson VF; DVT FREE Steering Committee (2004) A
prospective registry of 5,451 patients with ultrasound-confirmed deep vein
thrombosis. Am J Cardiol 93: 259–262.
42. Tillie-Leblond I, Marquette CH, Perez T, Scherpereel A, Zanetti C, et al. (2006)
Pulmonary embolism in patients with unexplained exacerbation of chronic
obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med 144:
390–396.
43. Ten VS, Pinsky DJ (2002) Endothelial response to hypoxia: physiologic
adaptation and pathologic dysfunction. Curr Opin Crit Care 8: 242–250.
44. Gertler JP, Weibe DA, Ocasio VH, Abbott WM (1991) Hypoxia induces
procoagulant activity in cultured human venous endothelium. J Vasc Surg 13:
428–433.
45. Gertler JP, Perry L, L’Italien G, Chung-Welch N, Cambria RP, et al. (1993)
Ambient oxygen tension modulates endothelial fibrinolysis. J Vasc Surg 18:
939–946.
46. Rota S, McWilliam NA, Baglin TP, Byrne CD (1998) Atherogenic lipoproteins
support assembly of the prothrombinase complex and thrombin generation:
modulation by oxidation and vitamin E. Blood 91: 508–515.
47. Bendz B, Rostrup M, Sevre K, Andersen TO, Sandset PM (2000) Association
between acute hypobaric hypoxia and activation of coagulation in human
beings. Lancet 356: 1657–1658.
48. Becker HF, Piper AJ, Flynn WE, McNamara SG, Grunstein RR, et al. (1999)
Breathing during sleep in patients with nocturnal desaturation. Am J Respir Crit
Care Med 159: 112–118.
49. Fletcher EC, Miller J, Divine GW, Fletcher JG, Miller T (1987) Nocturnal
oxyhemoglobin desaturation in COPD patients with arterial oxygen tensions
above 60 mm Hg. Chest 92: 604–608.
50. Krachman S, Minai OA, Scharf SM (2008) Sleep abnormalities and treatment
in emphysema. Proc Am Thorac Soc 5: 536–542.
51. Koo KW, Sax DS, Snider GL (1975) Arterial blood gases and pH during sleep in
chronic obstructive pulmonary disease. Am J Med 58: 663–670.
52. O’Reilly P, Bailey W (2007) Long-term continuous oxygen treatment in chronic
obstructive pulmonary disease: proper use, benefits and unresolved issues. Curr
Opin Pulm Med 13: 120–124.
53. American Thoracic Society (1995) Standards for the diagnosis and care of
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 152: S77–S121.
54. Plywaczewski R, Sliwinski P, Nowinski A, Kaminski D, Zielin ´ski J (2000)
Incidence of nocturnal desaturation while breathing oxygen in COPD patients
undergoing long-term oxygen therapy. Chest 117: 679–683.
55. Kim V, Benditt JO, Wise RA, Sharafkhaneh A (2008) Oxygen therapy in
chronic obstructive pulmonary disease. Proc Am Thorac Soc 5: 513–518.
Sleep Hypoxia on Emphysema
PLoS ONE | www.plosone.org 7 October 2010 | Volume 5 | Issue 10 | e13201